ReviewTrends in endocrinology and metabolism: TEM2013
Aldosterone and cardiovascular disease: the heart of the matter.
Review in Trends in endocrinology and metabolism: TEM, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 62 citations in OpenAlex.
- Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular-Kidney-Metabolic Syndrome.Diabetes, obesity & metabolism · 2026Review
- The Burden, Outcomes, and Management of Patients with Aldosterone Dysregulation: A Targeted Literature Review.Advances in therapy · 2026Review
- Review
- Role of the CCL5 and Its Receptor, CCR5, in the Genesis of Aldosterone-Induced Hypertension, Vascular Dysfunction, and End-Organ Damage.Hypertension (Dallas, Tex. : 1979) · 2024Article
- Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?Kidney & blood pressure research · 2024Review
- Relevance ofInternational journal of molecular sciences · 2023Review
- CaMKII as a Therapeutic Target in Cardiovascular Disease.Annual review of pharmacology and toxicology · 2023Review
- Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.Mayo Clinic proceedings. Innovations, quality & outcomes · 2022Review
- Aldosterone-Regulated Sodium Transport and Blood Pressure.Frontiers in physiology · 2022Review
- The Importance of Correlation between Aldosterone and Parathyroid Hormone in Patients with Primary Hyperparathyroidism.International journal of endocrinology · 2022Article
- Tolerability and Efficacy of Long-Term Medical Therapy in Primary Aldosteronism.Journal of the Endocrine Society · 2021Article
- Associations of trauma and posttraumatic stress disorder with aldosterone in women.Psychoneuroendocrinology · 2021Article
- Endocrine hypertension secondary to adrenal tumors: clinical course and predictive factors of clinical remission.Langenbeck's archives of surgery · 2021Article
- Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study.Clinical and translational science · 2020Article
- Review
- New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure.Journal of nephrology · 2020Review
- Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target.Heart failure reviews · 2019Review
- Association between elevated plasma aldosterone concentration and left atrial conduit function in hypertension.International Journal of Cardiology. Hypertension · 2019Article
- Familial hyperaldosteronism type III a novel case and review of literature.Reviews in endocrine & metabolic disorders · 2019Review
- Cardiac expression of neutrophil gelatinase-associated lipocalin in a model of cancer cachexia-induced cardiomyopathy.ESC heart failure · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Aldosterone contributes to the endocrine basis of heart failure, and studies on cardiac aldosterone signaling have reinforced its value as a therapeutic target. Recent focus has shifted to new roles of aldosterone that appear to depend on coexisting pathologic stimuli, cell type, and disease etiology. This review evaluates recent advances in mechanisms underlying aldosterone-induced cardiac disease and highlights the interplay between aldosterone and Ca(2+)/calmodulin dependent protein kinase II, whose hyperactivity during heart failure contributes to disease progression. Increasing evidence implicates aldosterone in diastolic dysfunction, and there is a need to develop more targeted therapeutics such as aldosterone synthase inhibitors and molecularly specific antioxidants. Despite accumulating knowledge, many questions still persist and will likely dictate areas of future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.